Long-term access study of alpelisib for current users
Treatments studied
Part of Cancer, Skin clinical trials.
This study allows people who are already taking alpelisib in another Novartis trial to continue receiving it long-term. The goal is to keep giving the drug to those who are benefiting from it, and to track safety over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking alpelisib in another Novartis study and are benefiting from it.
- Your doctor in the main study thinks it is safe for you to continue.
- You have been following the visit schedule in the main study well.
- You have not permanently stopped alpelisib in the main study for any reason.
- You do not have serious side effects from alpelisib that have not gotten better.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called alpelisib for children and adults with a rare overgrowth condition called PROS that is caused by a PIK3CA gene change. It aims to see if the drug can safely shrink overgrowth and improve symptoms.
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
This trial allows people who are already taking opnurasib in another Novartis study and seeing good results to keep receiving it. The goal is to let them continue treatment without interruption.
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
This study tests a new drug (LAE118) alone or with other treatments for advanced solid tumors, especially cancers with a specific genetic change (PIK3CA). It aims to see if the drug is safe and effective, and may help if standard treatments have stopped working.
Hear when a new PIK3CA-Related Overgrowth Spectrum (PROS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.